Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Recruiting now

Conditions studied: ESR1 Gene Mutation, Advanced Breast Cancer, Safety

In brief

This study is a prospective non-interventional real-world study enrolling patients with advanced breast cancer who are ER+/HER2- and have ESR1- gene mutations, collecting information on patients' complaints, physical examination, laboratory tests, imaging tests and adverse events to observe the safety of elacestrant treatment.

Key facts

Study ID
NCT06544577
Run by
SciClone Pharmaceuticals
People needed
350
Starts
2024-07-13
Expected to finish
2026-08-01
Last updated by the study team
2024-08-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.